Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.
Modvig S, Hallböök H, Madsen HO, Siitonen S, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Matuzeviciene R, Stoskus M, Marincevic M, Lilleorg A, Ehinger M, Norén-Nystrøm U, Toft N, Taskinen M, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Porwit A, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: rosthoj s. Leukemia. 2021 Jul;35(7):1894-1906. doi: 10.1038/s41375-020-01100-5. Epub 2020 Dec 14. Leukemia. 2021. PMID: 33318611 Free PMC article.
Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, Mäkipernaa A, Rosthøj S, Szumlanski C, Sørensen TM, Weinshilboum R. Schmiegelow K, et al. Among authors: rosthoj s. J Clin Oncol. 2003 Apr 1;21(7):1332-9. doi: 10.1200/JCO.2003.04.039. J Clin Oncol. 2003. PMID: 12663723 Clinical Trial.
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: rosthoj s. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, Wesenberg F, Rosthøj S, Schmiegelow K; Nordic Society of Pediatric Hematology, Oncology (NOPHO). Clemmensen KK, et al. Among authors: rosthoj s. Pediatr Blood Cancer. 2014 Apr;61(4):653-8. doi: 10.1002/pbc.24867. Epub 2013 Nov 22. Pediatr Blood Cancer. 2014. PMID: 24265159 Clinical Trial.
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology. Levinsen M, et al. Among authors: rosthoj s. Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3. Pediatr Blood Cancer. 2014. PMID: 24395436
171 results